Vonoprazan Provides Foundation For Newly Minted Phathom

Newly formed US venture Phathom, with industry veteran Tachi Yamada on board, has picked up selected rights to P-CAB molecule as Takeda continues to shed non-core assets and rights.

3d render illustration of human digestive system - front view
Phathom Looks To Build GI Business • Source: Shutterstock

Days after Takeda Pharmaceutical Co. Ltd. said it would continue to divest non-core assets to hone its strategic focus, the Japanese company has taken another step to that end by licensing out rights to a gastrointestinal drug in major western markets to a new US venture.

Phathom Pharmaceuticals has just been established to focus on the development and commercialization of novel treatments for gastrointestinal disorders, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category